Pfizer acquires Seagen for cancer treatment development

Current context: Pfizer will spend 43 billion dollar to buy Seagen for cancer research development. Pfizer will pay 229 dollar per share to Seagen.

• Both the companies will collaborate to provide Seagen’s antibody drug conjugate (ADC) with the help of Pfizer’s expertise in the field.
• Seagen is a Washington based company which is a biotech drug developer. It mainly specializes in cancer treatment.
• Seagen’s top seller, Adcertis, also made a deal with Pfizer’s Array BioPharma to treat breast cancer.
• Pfizer is a New York based company, has also contributed 11.6 billion dollars to migraine treatment developer Biohaven Pharmaceuticals.
• Pfizer concludes that Seagen can provide more than 10 billion dollars revenue until 2030 in the field of cancer treatment.

Question:

Q.1 Pfizer has collaborated with_______ for cancer treatment development.
a. ICICI
b. AIIMS
c. Seagen
d. IIT Kanpur